Literature DB >> 34708686

Incidence Trends for SARS-CoV-2 Alpha and Beta Variants, Finland, Spring 2021.

Ravi Kant, Phuoc Truong Nguyen, Soile Blomqvist, Mert Erdin, Hussein Alburkat, Maija Suvanto, Fathiah Zakham, Veera Salminen, Viktor Olander, Minna Paloniemi, Leena Huhti, Sara Lehtinen, Bruno Luukinen, Hanna Jarva, Hannimari Kallio-Kokko, Satu Kurkela, Maija Lappalainen, Hanna Liimatainen, Sari Hannula, Jani Halkilahti, Jonna Ikonen, Niina Ikonen, Otto Helve, Marianne Gunell, Tytti Vuorinen, Ilya Plyusnin, Erika Lindh, Pekka Ellonen, Tarja Sironen, Carita Savolainen-Kopra, Teemu Smura, Olli Vapalahti.   

Abstract

Severe acute respiratory syndrome coronavirus 2 Alpha and Beta variants became dominant in Finland in spring 2021 but had diminished by summer. We used phylogenetic clustering to identify sources of spreading. We found that outbreaks were mostly seeded by a few introductions, highlighting the importance of surveillance and prevention policies.

Entities:  

Keywords:  Alpha variant; Beta variant; COVID-19; Finland; SARS-CoV-2; coronavirus disease; epidemiology; infectious disease transmission; phylogeny; public health surveillance; respiratory infections; severe acute respiratory syndrome coronavirus 2; vaccination; vaccines; viruses

Mesh:

Year:  2021        PMID: 34708686      PMCID: PMC8632157          DOI: 10.3201/eid2712.211631

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


Several new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have emerged globally, most notably variants of concern Alpha (B.1.1.7) (), Beta (B1.351) (), Gamma (P.1) (), and most recently, Delta (B.1.617.2). Each variant is thought to pose an increased public health risk compared with the earlier wild-type strains that were circulating in 2020 because of >1 epidemiologic characteristics, such as higher transmissibility (), greater immune escape properties toward antibodies from previous SARS-CoV-2 infection (), lower response to current vaccines (), or more severe outcomes or increased mortality rates (). Detecting and monitoring these novel variants is essential in SARS-CoV-2 surveillance.

The Study

To assess the temporal epidemiologic dynamics among different variants of concern and identify spreading events and sources of SARS-CoV-2 cases detected in Finland, we began sequencing 400–1,000 virus samples per week collected during December 2020–May 2021 and analyzed the resulting genomes (n = 14,080), which are now available in the GISAID (https://www.gisaid.org) database. For quality control purposes, we removed all sequences with ≥2.0% gaps. We analyzed the resulting dataset (n = 9,160) with Pangolin (https://cov-lineages.org) () to identify lineages, from which we filtered Alpha and Beta variants for phylogenetic analyses. Each phylogenetic tree was computed from the filtered sequences and a global reference dataset consisting of 5 representative sequences, 1 sequence from the country of origin (England for Alpha, South Africa for Beta) and 4 randomly chosen from other countries containing the same lineage, for each date during December 2020–May 2021. The reference datasets included 841 genomes for Alpha variant and 775 genomes for Beta variant trees. We aligned sequences using MAFFT (https://mafft.cbrc.jp) () and removed gaps in the resulting alignments by trimming 50 characters from both the 5′ and 3′ ends. We then used the aligned sequences to compute the trees with a SARS-CoV-2–specific version of IQ-TREE 2 () using ModelFinder to identify and use the optimal nucleotide substitution model, performing 1,000 ultrafast bootstraps. We set the initial wild-type reference strain (GenBank accession no. NC_045512.2) as the outgroup. We assigned sequences to clusters using TreeCluster () based on an arbitrary branch length of 0.001 to identify major transmission chains. We collapsed clusters with ≤5 sequences for visualization purposes. By May 2021, there had been 93,393 laboratory-confirmed SARS-CoV-2 infections reported in Finland (); incidence peaks occurred in April and December 2020 and March 2021 (Appendix Figure 1, panel A). During this period, the weekly number of cases was as high as 4,900. National vaccinations began in late December 2020, and within 7 months, 3.5 million (62.8% of total population) persons had received first doses and 1.4 million (24.5% of total population) second doses (). Seroprevalence remained low (<2%) until February 2021 () but increased because of growing vaccination coverage (Appendix Figure 1, panel B). Throughout 2020, sequencing-based surveillance of the virus was conducted in the Hospital District of Helsinki and Uusimaa (HUS; Helsinki, Finland), which had the highest number of COVID-19 cases in the country (n = 21,742). Until December 18, 2020, only wild-type strains of SARS-CoV-2 had been detected, but the emergence of Alpha and Beta variants led to increased sequencing and sampling efforts at points of entry into Finland (i.e., airports, harbors, land border crossing sites) starting in week 51 of 2020. During December 2020–May 2021, a total of 14,080 SARS-CoV-2 genomes representing ≈20.4% of the PCR-confirmed SARS-CoV-2 infections (n = 65,921) were sequenced. During this period, the Alpha variant (5,370 total detections) comprised 58.6% of all cases, and its proportion in weekly counts rapidly increased from 3 (6.0%) of 50 in week 51 of 2020 to 602 (69.1%) of 871 in week 11 of 2021 (Appendix Figure 2). The highest proportion of Alpha variant cases was 240 (82.2%) of 292 detections in week 17. Beta variant incidence rose later and at a slower rate (1,049 total detections, 19.5% of all cases); the proportion in weekly case counts rose from 2 (1.7%) in week 2 of 2021 to 181 (23.1%) by week 12. The proportions of Alpha and Beta variants started to diminish in week 13. Only 1 Gamma variant case was recorded, in week 10, and the first Delta variant samples in Finland were collected during week 17. In addition, several variants of interest () were detected beginning in early January 2021: B.1.429 (2 detections), B.1.525 (25 detections), B.1.526 (1 detection), B.1.617.1 (6 detections), and P.2 (1 detection). Of the variants being monitored (), 18 cases of AT.1 and 29 of B.1.1.318 lineages were detected during this period. The clustering analysis of Alpha variants (Figure 1) showed 86 distinct clusters, of which 84 contained 5,270 sequences from Finland (57.5% of all sequences). The 13 largest clusters from Finland (total n = 3,669, 69.6%) had 132–663 sequences each. We detected 32 singletons (0.6% of Alpha detections) from Finland, suggesting that the epidemic was largely seeded from a few introductions, which aligns with the super-spreading properties of SARS-CoV-2 epidemiology. Most Alpha sequences were from the HUS district (n = 3,476, 64.7% of cases). We included all available high-quality sequences from random populations from Finland and thus included data from both mild and severe cases. However, a proportion of the samples from the HUS region came from points of entry into Finland and other hospital districts. The proportions of these imported samples varied over the sampling period depending on travel restrictions and hospitalized case-patients, which may have led to nonrandomized sampling from the HUS region.
Figure 1

Phylogenetic tree of severe acute respiratory syndrome coronavirus 2 Alpha (B.1.1.7) variant clusters from Finland and sequence distribution. The tree (A) shows 86 clusters with ≥5 sequences (red circles), of which 84 contain 5,270 sequences sampled in Finland using TreeCluster, and 32 Finland singletons (white circles). The tree was constructed by using IQ-TREE 2 () with 1,000 ultrafast bootstraps. Each row in subsequent graphs is equivalent to a cluster and shows the number of sequences from Finland (B) and the proportion of sequences per region of Finland (C). Regions of Finland: 1, Åland Islands; 2, Central Finland Health Care District; 3, Central Ostrobothnia Hospital District; 4, East Savo Hospital District; 5, Hospital District of Helsinki and Uusimaa; 6, Hospital District of South Ostrobothnia; 7, Hospital District of Southwest Finland; 8, Kainuu Social and Health Care Joint Authority; 9, Kanta-Häme Hospital District; 10, Länsi-Pohja Healthcare District; 11, Lapland Hospital District; 12, North Karelia Hospital District; 13, North Ostrobothnia Hospital District; 14, North Savo Hospital District; 15, Päijät-Häme Hospital District; 16, Pirkanmaa Hospital District; 17, Satakunta Hospital District; 18, Social and Health Services in Kymenlaakso; 19, South Karelia Social and Health Care District; 20, South Savo Hospital District; 21, Vaasa Hospital District.

Phylogenetic tree of severe acute respiratory syndrome coronavirus 2 Alpha (B.1.1.7) variant clusters from Finland and sequence distribution. The tree (A) shows 86 clusters with ≥5 sequences (red circles), of which 84 contain 5,270 sequences sampled in Finland using TreeCluster, and 32 Finland singletons (white circles). The tree was constructed by using IQ-TREE 2 () with 1,000 ultrafast bootstraps. Each row in subsequent graphs is equivalent to a cluster and shows the number of sequences from Finland (B) and the proportion of sequences per region of Finland (C). Regions of Finland: 1, Åland Islands; 2, Central Finland Health Care District; 3, Central Ostrobothnia Hospital District; 4, East Savo Hospital District; 5, Hospital District of Helsinki and Uusimaa; 6, Hospital District of South Ostrobothnia; 7, Hospital District of Southwest Finland; 8, Kainuu Social and Health Care Joint Authority; 9, Kanta-Häme Hospital District; 10, Länsi-Pohja Healthcare District; 11, Lapland Hospital District; 12, North Karelia Hospital District; 13, North Ostrobothnia Hospital District; 14, North Savo Hospital District; 15, Päijät-Häme Hospital District; 16, Pirkanmaa Hospital District; 17, Satakunta Hospital District; 18, Social and Health Services in Kymenlaakso; 19, South Karelia Social and Health Care District; 20, South Savo Hospital District; 21, Vaasa Hospital District. Beta variants formed 76 distinct clusters, of which 56 contained 910 sequences from Finland (9.9% of all sequences from Finland) (Figure 2). We also identified 33 singletons, of which 23 were from Finland (2.2% of Beta detections). In total, there might have been 79 introductions from other countries, which seeded 1 major cluster (>100 Finland sequences) containing 167 sequences (15.9% of cases). Most Beta sequences were also from the HUS hospital district (n = 505, 48.1% of cases). Hospital district reports were based on data from the Finnish Institute for Health and Welfare (https://sampo.thl.fi), HUS, and Fimlab (https://fimlab.fi).
Figure 2

Phylogenetic trees of severe acute respiratory syndrome coronavirus 2 Beta (B1.351) variant clusters from Finland and sequence distribution. The tree (A) shows 76 clusters with ≥5 sequences (red circles), of which 48 contain 898 sequences sampled in Finland using TreeCluster (), and 23 Finland singletons (white circles) from 33. The tree was constructed by using IQ-TREE 2 () with 1,000 ultrafast bootstraps. Each row in subsequent panels is equivalent to a cluster and shows the number of sequences from Finland (B) and the proportion of sequences per region of from Finland (C). Regions of Finland: 1, Central Finland Health Care District; 2, East Savo Hospital District; 3, Hospital District of Helsinki and Uusimaa; 4, Hospital District of South Ostrobothnia; 5, Hospital District of Southwest Finland; 6, Kainuu Social and Health Care Joint Authority; 7, Kanta-Häme Hospital District; 8, Länsi-Pohja Healthcare District; 9, Lapland Hospital District; 10, North Karelia Hospital District; 11, North Ostrobothnia Hospital District; 12, North Savo Hospital District; 13, Päijät-Häme Hospital District; 14, Pirkanmaa Hospital District; 15, Satakunta Hospital District; 16, Social and Health Services in Kymenlaakso; 17, South Karelia Social and Health Care District; 18, South Savo Hospital District; 19, Vaasa Hospital District,

Phylogenetic trees of severe acute respiratory syndrome coronavirus 2 Beta (B1.351) variant clusters from Finland and sequence distribution. The tree (A) shows 76 clusters with ≥5 sequences (red circles), of which 48 contain 898 sequences sampled in Finland using TreeCluster (), and 23 Finland singletons (white circles) from 33. The tree was constructed by using IQ-TREE 2 () with 1,000 ultrafast bootstraps. Each row in subsequent panels is equivalent to a cluster and shows the number of sequences from Finland (B) and the proportion of sequences per region of from Finland (C). Regions of Finland: 1, Central Finland Health Care District; 2, East Savo Hospital District; 3, Hospital District of Helsinki and Uusimaa; 4, Hospital District of South Ostrobothnia; 5, Hospital District of Southwest Finland; 6, Kainuu Social and Health Care Joint Authority; 7, Kanta-Häme Hospital District; 8, Länsi-Pohja Healthcare District; 9, Lapland Hospital District; 10, North Karelia Hospital District; 11, North Ostrobothnia Hospital District; 12, North Savo Hospital District; 13, Päijät-Häme Hospital District; 14, Pirkanmaa Hospital District; 15, Satakunta Hospital District; 16, Social and Health Services in Kymenlaakso; 17, South Karelia Social and Health Care District; 18, South Savo Hospital District; 19, Vaasa Hospital District,

Conclusions

Altogether, our study shows both Alpha and Beta variants emerging early and rapidly beginning in December 2020. Most (98.2% Alpha, 86.8% Beta) formed clusters, and only a small proportion (0.6% Alpha, 2.2% Beta) were singletons. Because the singletons represent a small fraction of the sequences and many were transmitted directly from travelers, it is likely that a few introductions were able to seed the epidemic. The Alpha and Beta variants dominated detected SARS-CoV-2 cases, although at lower numbers for Beta, during early 2021. Despite the rapid emergence of these variants, their incidence fell sharply (Appendix Figure 1, panel A). Incidence in Finland has been low compared with other countries in Europe, permitting use of more moderately restrictive prevention measures. Incidence, and therefore seroprevalence, remained relatively low until vaccines became available. Practices and policies enacted in Finland, including frequent testing, contact tracing, isolation, quarantine, and other nonpharmaceutical interventions, helped effectively interrupt chains of transmission, and ongoing national efforts have resulted in most of the population of Finland receiving at least the first vaccine dose. These findings suggest that with proper surveillance and preventative measures, along with moderate restriction compliance, the spread SARS-CoV-2 could be mitigated effectively.

Appendix

Additional information on SARS-CoV2 Alpha and Beta variants in Finland.
  10 in total

1.  TreeCluster: Clustering biological sequences using phylogenetic trees.

Authors:  Metin Balaban; Niema Moshiri; Uyen Mai; Xingfan Jia; Siavash Mirarab
Journal:  PLoS One       Date:  2019-08-22       Impact factor: 3.240

2.  MAFFT multiple sequence alignment software version 7: improvements in performance and usability.

Authors:  Kazutaka Katoh; Daron M Standley
Journal:  Mol Biol Evol       Date:  2013-01-16       Impact factor: 16.240

3.  Detection of a SARS-CoV-2 variant of concern in South Africa.

Authors:  Houriiyah Tegally; Eduan Wilkinson; Marta Giovanetti; Arash Iranzadeh; Vagner Fonseca; Jennifer Giandhari; Deelan Doolabh; Sureshnee Pillay; Emmanuel James San; Nokukhanya Msomi; Koleka Mlisana; Anne von Gottberg; Sibongile Walaza; Mushal Allam; Arshad Ismail; Thabo Mohale; Allison J Glass; Susan Engelbrecht; Gert Van Zyl; Wolfgang Preiser; Francesco Petruccione; Alex Sigal; Diana Hardie; Gert Marais; Nei-Yuan Hsiao; Stephen Korsman; Mary-Ann Davies; Lynn Tyers; Innocent Mudau; Denis York; Caroline Maslo; Dominique Goedhals; Shareef Abrahams; Oluwakemi Laguda-Akingba; Arghavan Alisoltani-Dehkordi; Adam Godzik; Constantinos Kurt Wibmer; Bryan Trevor Sewell; José Lourenço; Luiz Carlos Junior Alcantara; Sergei L Kosakovsky Pond; Steven Weaver; Darren Martin; Richard J Lessells; Jinal N Bhiman; Carolyn Williamson; Tulio de Oliveira
Journal:  Nature       Date:  2021-03-09       Impact factor: 49.962

4.  Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil.

Authors:  Nuno R Faria; Thomas A Mellan; Charles Whittaker; Ingra M Claro; Darlan da S Candido; Swapnil Mishra; Oliver G Pybus; Seth Flaxman; Samir Bhatt; Ester C Sabino; Myuki A E Crispim; Flavia C S Sales; Iwona Hawryluk; John T McCrone; Ruben J G Hulswit; Lucas A M Franco; Mariana S Ramundo; Jaqueline G de Jesus; Pamela S Andrade; Thais M Coletti; Giulia M Ferreira; Camila A M Silva; Erika R Manuli; Rafael H M Pereira; Pedro S Peixoto; Moritz U G Kraemer; Nelson Gaburo; Cecilia da C Camilo; Henrique Hoeltgebaum; William M Souza; Esmenia C Rocha; Leandro M de Souza; Mariana C de Pinho; Leonardo J T Araujo; Frederico S V Malta; Aline B de Lima; Joice do P Silva; Danielle A G Zauli; Alessandro C de S Ferreira; Ricardo P Schnekenberg; Daniel J Laydon; Patrick G T Walker; Hannah M Schlüter; Ana L P Dos Santos; Maria S Vidal; Valentina S Del Caro; Rosinaldo M F Filho; Helem M Dos Santos; Renato S Aguiar; José L Proença-Modena; Bruce Nelson; James A Hay; Mélodie Monod; Xenia Miscouridou; Helen Coupland; Raphael Sonabend; Michaela Vollmer; Axel Gandy; Carlos A Prete; Vitor H Nascimento; Marc A Suchard; Thomas A Bowden; Sergei L K Pond; Chieh-Hsi Wu; Oliver Ratmann; Neil M Ferguson; Christopher Dye; Nick J Loman; Philippe Lemey; Andrew Rambaut; Nelson A Fraiji; Maria do P S S Carvalho
Journal:  Science       Date:  2021-04-14       Impact factor: 47.728

5.  IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the Genomic Era.

Authors:  Bui Quang Minh; Heiko A Schmidt; Olga Chernomor; Dominik Schrempf; Michael D Woodhams; Arndt von Haeseler; Robert Lanfear
Journal:  Mol Biol Evol       Date:  2020-05-01       Impact factor: 16.240

6.  Kinetics of Neutralizing Antibodies of COVID-19 Patients Tested Using Clinical D614G, B.1.1.7, and B 1.351 Isolates in Microneutralization Assays.

Authors:  Jenni Virtanen; Ruut Uusitalo; Essi M Korhonen; Kirsi Aaltonen; Teemu Smura; Suvi Kuivanen; Sari H Pakkanen; Sointu Mero; Anu Patjas; Marianna Riekkinen; Anu Kantele; Visa Nurmi; Klaus Hedman; Jussi Hepojoki; Tarja Sironen; Eili Huhtamo; Olli Vapalahti
Journal:  Viruses       Date:  2021-05-26       Impact factor: 5.048

7.  Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021.

Authors:  Finlay Campbell; Brett Archer; Henry Laurenson-Schafer; Yuka Jinnai; Franck Konings; Neale Batra; Boris Pavlin; Katelijn Vandemaele; Maria D Van Kerkhove; Thibaut Jombart; Oliver Morgan; Olivier le Polain de Waroux
Journal:  Euro Surveill       Date:  2021-06

8.  Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7.

Authors:  Karla Diaz-Ordaz; Ruth H Keogh; Nicholas G Davies; Christopher I Jarvis; W John Edmunds; Nicholas P Jewell
Journal:  Nature       Date:  2021-03-15       Impact factor: 69.504

9.  COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants.

Authors:  Pinja Jalkanen; Pekka Kolehmainen; Hanni K Häkkinen; Moona Huttunen; Paula A Tähtinen; Rickard Lundberg; Sari Maljanen; Arttu Reinholm; Sisko Tauriainen; Sari H Pakkanen; Iris Levonen; Arttu Nousiainen; Taru Miller; Hanna Välimaa; Lauri Ivaska; Arja Pasternack; Rauno Naves; Olli Ritvos; Pamela Österlund; Suvi Kuivanen; Teemu Smura; Jussi Hepojoki; Olli Vapalahti; Johanna Lempainen; Laura Kakkola; Anu Kantele; Ilkka Julkunen
Journal:  Nat Commun       Date:  2021-06-28       Impact factor: 14.919

  10 in total
  8 in total

1.  Cov2clusters: genomic clustering of SARS-CoV-2 sequences.

Authors:  Benjamin Sobkowiak; Kimia Kamelian; James E A Zlosnik; John Tyson; Anders Gonçalves da Silva; Linda M N Hoang; Natalie Prystajecky; Caroline Colijn
Journal:  BMC Genomics       Date:  2022-10-19       Impact factor: 4.547

2.  Spatiotemporal clustering patterns and sociodemographic determinants of COVID-19 (SARS-CoV-2) infections in Helsinki, Finland.

Authors:  Mika Siljander; Ruut Uusitalo; Petri Pellikka; Sanna Isosomppi; Olli Vapalahti
Journal:  Spat Spatiotemporal Epidemiol       Date:  2022-02-05

3.  ClusTRace, a bioinformatic pipeline for analyzing clusters in virus phylogenies.

Authors:  Teemu Smura; Ravi Kant; Ilya Plyusnin; Phuoc Thien Truong Nguyen; Tarja Sironen; Olli Vapalahti
Journal:  BMC Bioinformatics       Date:  2022-05-28       Impact factor: 3.307

4.  Scent dogs in detection of COVID-19: triple-blinded randomised trial and operational real-life screening in airport setting.

Authors:  Anu Kantele; Juuso Paajanen; Soile Turunen; Sari H Pakkanen; Anu Patjas; Laura Itkonen; Elina Heiskanen; Maija Lappalainen; Loic Desquilbet; Olli Vapalahti; Anna Hielm-Björkman
Journal:  BMJ Glob Health       Date:  2022-05

5.  Introduction and Rapid Spread of SARS-CoV-2 Omicron Variant and Dynamics of BA.1 and BA.1.1 Sublineages, Finland, December 2021.

Authors:  Hanna Vauhkonen; Phuoc Truong Nguyen; Ravi Kant; Ilja Plyusnin; Mert Erdin; Satu Kurkela; Hanna Liimatainen; Niina Ikonen; Soile Blomqvist; Kirsi Liitsola; Erika Lindh; Otto Helve; Hanna Jarva; Raisa Loginov; Aino Palva; Tiina Hannunen; Sari Hannula; Mikko Parry; Paula Kauppi; Antti Vaheri; Tarja Sironen; Maija Lappalainen; Carita Savolainen-Kopra; Teemu Smura; Olli Vapalahti
Journal:  Emerg Infect Dis       Date:  2022-04-04       Impact factor: 16.126

6.  Genomic and epidemiological report of the recombinant XJ lineage SARS-CoV-2 variant, detected in northern Finland, January 2022.

Authors:  Erika Lindh; Teemu Smura; Soile Blomqvist; Kirsi Liitsola; Hanna Vauhkonen; Laura Savolainen; Jaana Ikonen; Jukka Ronkainen; Jyri Taskila; Tea Taskila; Pertti Sakaranaho; Carita Savolainen-Kopra; Olli Vapalahti; Niina Ikonen
Journal:  Euro Surveill       Date:  2022-04

7.  Respiratory virus circulation in children after relaxation of COVID-19 restrictions in fall 2021-A nationwide register study in Finland.

Authors:  Ilari Kuitunen; Miia Artama; Marjut Haapanen; Marjo Renko
Journal:  J Med Virol       Date:  2022-05-23       Impact factor: 20.693

8.  The evaluation of an automated mariPOC SARS-CoV-2 antigen test compared to RT-qPCR SARS-CoV-2 assay and comparison of its sensitivity in Delta- and Omicron-variant samples.

Authors:  Marcela Krutova; Marie Brajerova; Zdenek Kepka; Ales Briksi; Petr Hubacek; Pavel Drevinek
Journal:  Influenza Other Respir Viruses       Date:  2022-09-06       Impact factor: 5.606

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.